Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sarepta rapeutics

Dow Jones Futures Fall: Market Rally Reeling As Fed's Powell Signals Higher Peak Rate

Futures fell after the stock market sold off Wednesday on Fed chief Jerome Powell hinting at slower rate hikes but also a higher peak rate.

Investors Business Daily

Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool

Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool

Sarepta Therapeutics and Albemarle are among several companies in the IBD 50 whose stocks are above their 10-week lines.

Investors Business Daily

FDA Faces a Tough Call - and Again Risks Its Credibility

FDA Faces a Tough Call - and Again Risks Its Credibility

Another controversial neuroscience drug could soon be approved.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

Did Sarepta Therapeutics Just Unveil a Breakthrough?

The leading gene therapy developer just bolstered its technology platform.

The Sarepta Therapeutics Pipeline No One is Talking About

Gene therapy and gene editing get all the glory, but investors shouldn't overlook an emerging group of tools.

Where Sarepta Therapeutics Stands With Analysts

Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.

Why Wall Street Doubts This Biotech Penny Stock Will Be Delisted

Why Wall Street Doubts This Biotech Penny Stock Will Be Delisted

The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.

Expert Ratings for Sarepta Therapeutics

Expert Ratings for Sarepta Therapeutics

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Sarepta Therapeutics: Q1 Earnings Insights

Sarepta Therapeutics: Q1 Earnings Insights

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Sarepta Therapeutics's Earnings: A Preview

Sarepta Therapeutics's Earnings: A Preview

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Sarepta Therapeutics will report an earnings per share (EPS) of $-1.27.

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating

Sarepta Therapeutics sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Sarepta Therapeutics's Earnings Outlook

Sarepta Therapeutics's Earnings Outlook

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Sarepta Therapeutics will report an earnings per share (EPS) of $-1.13.

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play